logo

For the Inventor, By the Inventor

Incheon, South Korea

Hyoun Rok Paik

This inventor holds 18 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Bacteriophage Research. Top assignee: Intron Biotechnology, Inc.. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hyoun Rok Paik. Retrieved from https://idiyas.com/inventor/hyoun-rok-paik

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 22(Granted Patents)


Location History:

  • Jeollanam-do, KR (2016)
  • Incheon, KR (2018 - 2022)

Company Filing History:

goldMedal18 out of 69 
 
Intron Biotechnology, Inc.
 patents

Years Active: 2016-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Bacteriophage
Antibacterial Protein
Proliferation Inhibition
Pathogenic Bacteria
Bacteriolytic Ability
Clostridium Perfringens
Clo-PEP-2
Pse-AEP-4
STP-2
Esc-COP-7
EFAL-2
Bacterial Inhibition
18 patents (USPTO):Explore Patents
1. 12114664 - bacteriophage STP-2 and use thereof for inhibiting proliferation of (2024-10-15),
2. 11529406 - bacteriophage Clo-PEP-2 and use for inhibitingproliferation of same (2022-12-20),
3. 11497216 - bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of (2022-11-15),
4. 11492378 - Antibacterial protein EFAL-2 having bacteriolytic ability with respect to (2022-11-08),
5. 11458177 - bacteriophage Ent-FAP-4 and use for inhibitingproliferation of same (2022-10-04),
6. 11457635 - bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of (2022-10-04),
7. 11412760 - bacteriophage Esc-COP-7, and use thereof for suppressing proliferation of pathogenic (2022-08-16),
8. 11213050 - bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenicthereof (2022-01-04),
9. 10894068 - bacteriophage Bor-BRP-1, and use thereof for inhibition of proliferation ofbacteria (2021-01-19),
10. 10568917 - bacteriophage Pas-MUP-1 and use thereof for inhibiting proliferation of (2020-02-25),
11. 10265356 - [object Object] (2019-04-23),
12. 10265355 - [object Object] (2019-04-23),
13. 10265354 - [object Object] (2019-04-23),
14. 10265353 - [object Object] (2019-04-23),
15. 10227571 - [object Object] (2019-03-12),

Title: Innovations in Bacteriophage Therapy: The Patents of Hyoun Rok Paik

Introduction

Hyoun Rok Paik, based in Incheon, South Korea, is a prominent inventor specializing in bacteriophage research with a remarkable portfolio of 18 patents. His work primarily focuses on the development of innovative treatments that utilize bacteriophages, which are viruses that infect and kill bacteria, offering significant potential for combating antibiotic resistance and improving healthcare solutions.

Latest Patents

Among his latest patents, two notable inventions are the bacteriophage STP-2 and bacteriophage Clo-PEP-2. The invention concerning bacteriophage STP-2 (Accession number: KCTC 12853BP) highlights its ability to destroy harmful bacteria and presents a method for preventing and treating diseases associated with bacterial proliferation. This bacteriophage is characterized by a specific genome represented by SEQ ID NO:1.

Similarly, his work on bacteriophage Clo-PEP-2 (Accession number: KCTC 13185BP) emphasizes its capacity to eliminate bacteria and outlines a method for preventing or treating diseases caused by bacterial infections. This invention showcases the application of bacteriophage Clo-PEP-2 in therapeutic compositions, further advancing the field of bacteriophage therapy.

Career Highlights

Hyoun Rok Paik is currently associated with Intron Biotechnology, Inc., where his expertise is leveraged to push the boundaries of bacteriophage therapeutic applications. His contributions have considerably influenced the landscape of biological research and treatment methodologies, positioning him as a key innovator in the industry.

Collaborations

Throughout his career, Paik has collaborated with notable colleagues such as Seong Jun Yoon and Sang Hyeon Kang. These partnerships have facilitated the exchange of ideas and expertise, enhancing the research outcomes and leading to the development of his groundbreaking patents.

Conclusion

Hyoun Rok Paik’s innovative work in the field of bacteriophage therapy represents a significant advancement in medical science. With 18 patents to his name, his contributions to the development of bacteriophages like STP-2 and Clo-PEP-2 reflect his commitment to finding effective solutions to combat bacterial diseases. As research in this domain continues to evolve, Paik's inventions will likely play an instrumental role in shaping future therapeutic approaches.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…